Ameriprise Financial Inc. Takes $452,000 Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Ameriprise Financial Inc. bought a new stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 53,382 shares of the specialty pharmaceutical company's stock, valued at approximately $452,000. Ameriprise Financial Inc. owned about 0.11% of KalVista Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also made changes to their positions in the company. Aquatic Capital Management LLC purchased a new stake in shares of KalVista Pharmaceuticals in the fourth quarter valued at about $44,000. Tower Research Capital LLC TRC raised its position in shares of KalVista Pharmaceuticals by 666.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company's stock worth $54,000 after purchasing an additional 5,502 shares during the last quarter. Legal & General Group Plc lifted its stake in KalVista Pharmaceuticals by 22.5% in the 4th quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company's stock valued at $69,000 after buying an additional 1,494 shares in the last quarter. Martin Worley Group acquired a new stake in KalVista Pharmaceuticals during the 4th quarter valued at $86,000. Finally, Algert Global LLC acquired a new stake in KalVista Pharmaceuticals during the 4th quarter valued at $88,000.

KalVista Pharmaceuticals Trading Up 4.1%

KALV stock traded up $0.56 during trading on Friday, reaching $14.36. The stock had a trading volume of 544,245 shares, compared to its average volume of 433,407. The firm has a fifty day moving average price of $12.01 and a 200 day moving average price of $10.57. The company has a market capitalization of $713.92 million, a P/E ratio of -3.95 and a beta of 0.05. KalVista Pharmaceuticals, Inc. has a 1-year low of $7.30 and a 1-year high of $15.50.

Analyst Ratings Changes

KALV has been the topic of a number of recent research reports. Needham & Company LLC restated a "buy" rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a report on Tuesday, April 8th. HC Wainwright reissued a "buy" rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a research note on Friday, March 14th. Finally, Jones Trading restated a "buy" rating and issued a $30.00 price target on shares of KalVista Pharmaceuticals in a report on Wednesday, March 26th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $24.83.

Insider Activity at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 2,776 shares of the firm's stock in a transaction on Monday, May 19th. The shares were sold at an average price of $11.84, for a total transaction of $32,867.84. Following the completion of the transaction, the insider now directly owns 106,611 shares of the company's stock, valued at $1,262,274.24. This trade represents a 2.54% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Venrock Healthcare Capital Par bought 25,000 shares of the business's stock in a transaction dated Wednesday, April 9th. The stock was bought at an average price of $9.42 per share, for a total transaction of $235,500.00. Following the purchase, the insider now owns 5,303,985 shares in the company, valued at approximately $49,963,538.70. This represents a 0.47% increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders sold 8,730 shares of company stock valued at $102,226. Insiders own 10.50% of the company's stock.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).